Needham Reiterates Buy on Cara Therapeutics, Maintains $5 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Joseph Stringer has reiterated a Buy rating on Cara Therapeutics (NASDAQ:CARA) and maintained a $5 price target.
May 23, 2024 | 10:27 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Joseph Stringer has reiterated a Buy rating on Cara Therapeutics and maintained a $5 price target, indicating continued confidence in the company's prospects.
The reiteration of a Buy rating and maintenance of a $5 price target by a reputable analyst suggests positive sentiment and confidence in Cara Therapeutics' future performance. This is likely to have a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100